Pharma Export Boom: Sun Pharma, Dr Reddy's, Cipla — Which Stock Will Capture US Market Growth Post-Trade Deal?
Monday, February 9, 2026
Comment
For investors seeking maximum leverage from the trade deal, Dr. Reddy's offers the most compelling risk-reward profile.
from NDTV Profit - Latest https://ift.tt/i4pQ7Xh
from NDTV Profit - Latest https://ift.tt/i4pQ7Xh
0 Response to "Pharma Export Boom: Sun Pharma, Dr Reddy's, Cipla — Which Stock Will Capture US Market Growth Post-Trade Deal?"
Post a Comment